Neurodegenerative Disease Treatment Market Size to Reach USD 118.5 Billion by 2033

Market Overview

The global neurodegenerative disease treatment market size was valued at USD 78.3 Billion in 2024. It is projected to reach USD 118.5 Billion by 2033, growing at a CAGR of 4.48% during the forecast period 2025-2033. Neurodegenerative diseases involve progressive degradation of neurons in the central or peripheral nervous system. Increasing prevalence of related disorders and advancements in molecular diagnostic techniques are driving market expansion. 

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Neurodegenerative Disease Treatment Market Key Takeaways

• Current Market Size (2024): USD 78.3 Billion
• CAGR (2025-2033): 4.48%
• Forecast Period: 2025-2033
• Neurodegenerative diseases cause progressive neuron degeneration in CNS or PNS affecting physical and mental functions.
• Molecular diagnostics such as biomarkers and imaging spectroscopy are advancing early diagnosis and treatment.
• Increasing prevalence of tumors, stroke, and aging populations are major risk factors driving demand.
• Researchers are developing minimally invasive screening tests and combining neuropathology with molecular biology.
• Governments and NGOs promote health education campaigns to raise awareness of risk factors.

Request for a Free Sample of this Report: https://www.imarcgroup.com/neurodegenerative-disease-treatment-market/requestsample

Market Growth Factors

Brain tumors and strokes are caused by drinking excessive amounts of alcohol. The aging of populations causes tumors, stroke, and neurodegenerative diseases to occur more frequently. There is also a need in molecular diagnostic tests for Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease) for early screening and prevention purposes.

Neuropathologists also research neuropathology using molecular biology techniques to classify these diseases and assist in developing diagnostic techniques. The techniques will be more specific and less intrusive to test for early neurodegenerative disease, which may imply treatment and affect the outcome for the patient with neurodegenerative disease.

Government initiatives by several nations and NGOs to promote health education and to create awareness regarding the risk factors for neurodegenerative diseases, as well as to improve the healthcare infrastructure, are expected to support growth in the neuropathic pain treatment market. An increase in disposable income is also expected to fuel market sales.

Market Segmentation

Breakup by Indication:

• Multiple Sclerosis: Covers treatments targeting this chronic CNS disease characterized by immune-mediated degradation of myelin.
• Parkinson’s Disease: Focuses on therapeutic approaches managing symptoms related to this progressive nervous system disorder.
• Alzheimer’s Disease: Includes drugs and therapies addressing cognitive decline and memory loss.
• Spinal Muscular Atrophy (SMA): Encompasses treatment options for this genetic disorder impacting motor neurons.
• Huntington’s Disease: Covers interventions for this inherited brain disorder causing motor, cognitive, and psychiatric symptoms.
• Others: Includes treatments for other less common neurodegenerative diseases.

Breakup by Drug Type:

• N-methyl-D-aspartate Receptor Antagonists: Drugs that block NMDA receptors to manage neurodegenerative symptoms.
• Selective Serotonin Reuptake Inhibitors: Therapeutics that regulate serotonin levels to influence neurological function.
• Dopamine Inhibitors: Medications targeting dopamine pathways affecting neurodegenerative disorders.
• Others: Other drug types used in treatment protocols.

Breakup by Route of Administration:

• Oral: Medications administered through the mouth.
• Injectable: Treatments delivered via injection.
• Others: Other administration methods.

Breakup by Distribution Channel:

• Hospital Pharmacies: Distribution through hospital-based pharmaceutical services.
• Retail Pharmacies: Drug dispensation through retail outlets.
• Others: Alternative distribution channels.

Breakup by Region:

• North America: Includes United States and Canada.
• Asia-Pacific: Covers China, Japan, India, South Korea, Australia, Indonesia, and others.
• Europe: Comprises Germany, France, United Kingdom, Italy, Spain, Russia, and others.
• Latin America: Includes Brazil, Mexico, and others.
• Middle East and Africa: Covers various countries in these regions.

Regional Insights

North America is the second largest contributor to the growth of the global neurodegenerative disease therapeutics market. Major countries in this region are the U.S. and Canada. The US and Canada are preferred neurodegenerative disease therapeutics markets given their advanced health infrastructure, research, and awareness. The case study does not provide regional information on market share and international compound annual growth rate.

Key Players

• Biogen
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A
• Teva Pharmaceutical Industries Ltd.
• UCB S.A

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask Our Expert & Browse Full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=3102&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302